Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen's Oncology Strategy: Building A Pipeline Of Novel Paradigm-Changing Drugs

Jun 11 2019

• By Mandy Jackson

T-cells attacking cancer_1200x675 — Amgen's BiTE molecules recruit T-cells to targeted tumors. • Source: Shutterstock

Related Content

FDA Grants Blincyto Accelerated Approval Based On MRD Response Endpoint

Mar 30 2018

Amgen buying Onyx for $10.4 billion to be bigger player in cancer therapies

Aug 26 2013

AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches

Dec 06 2018

Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach

Jun 04 2019

Pfizer granted accelerated OK for Xalkori in NSCLC ahead of schedule

Aug 29 2011

Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond

Sep 08 2016

ASH Preview: BCMA-Targeting CAR-Ts And Bispecifics Hog The Spotlight

Nov 29 2018

Amgen gains early US win for BiTE antibody Blincyto

Dec 04 2014

Amgen to swallow $1.16B Micromet in one BiTE, like a cytotoxic T cell on a tumour

Jan 27 2012

Related Companies

Amgen, Inc.

Merck & Co., Inc.

Pfizer Inc.

Micromet, Inc.

AbbVie Inc.

Genentech, Inc.

AstraZeneca PLC

Les Laboratoires Servier

Novartis AG

Onyx Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Johnson & Johnson

Additional Topics

Innovation Platform Technologies Clinical Trials Companies Research & Development Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window